PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...
GLP-1 RA use is associated with improved survival and lower hospitalization rates in patients with type 2 diabetes receiving cancer therapy.
Kayshild is recommended for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis and ...
The researchers found that patients taking GLP-1 RAs had a significantly reduced incidence of revision FESS versus the non-GLP-1 RA group at one-year (risk ratio [RR], 0.64) and five-year follow-up ...
GI side effects. These are common with these medications and can include nausea, diarrhea, abdominal pain, and vomiting. “Symptoms are often tolerable in younger patients; they can precipitate serious ...
FDA requests removal of suicidal ideation warnings from GLP-1 RA labels after meta-analysis shows no increased risk compared with placebo.
BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the ...
GLP-1RA use improves major cardiovascular and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is ...
Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...
Association persisted after removing patients with previous diagnosis of gastroesophageal reflux. (HealthDay News) — For patients with type 2 diabetes, there is an association between glucagon-like ...
US pharma giant Pfizer today announced positive top-line results from the Phase IIb VESPER-3 study investigating monthly ...
Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results